AIMS: To study the implications of European guidelines on the use of antihypertensives and/or lipid-lowering drugs (LLDs) for primary prevention in a Norwegian population. METHODS AND RESULTS: The Tromsø study is a population-based study in the municipality Tromsø, Norway (from 1974 to till now). This analysis includes 45-79-year-old participants in 2001 (n = 6362, attendance rate 86%). From the age of 60 years in men and 70 years in women, almost all participants were defined as high-risk individuals according to the European guidelines, with established cardiovascular disease, diabetes, or a 10-year risk score of > or =5%. In the primary prevention subgroup of the 45-64-year-olds, recommended antihypertensive and/or LLD use would be higher in men only, 42% compared with 12% on current medication. Among the 65-79-year-olds, >90% would be eligible for antihypertensives and/or LLDs in both sexes when compared with current treatment rates of <30%. In total, 40% of all participants aged 45-79 would be candidates for primary prevention, compared with 15% on current medication. CONCLUSION: The implementation of the European guidelines could imply a doubling of the numbers of Norwegian adults on cardiovascular medication for primary prevention. Contributors to the increase would be more frequent drug use in men and elderly people, particularly for LLD use.
AIMS: To study the implications of European guidelines on the use of antihypertensives and/or lipid-lowering drugs (LLDs) for primary prevention in a Norwegian population. METHODS AND RESULTS: The Tromsø study is a population-based study in the municipality Tromsø, Norway (from 1974 to till now). This analysis includes 45-79-year-old participants in 2001 (n = 6362, attendance rate 86%). From the age of 60 years in men and 70 years in women, almost all participants were defined as high-risk individuals according to the European guidelines, with established cardiovascular disease, diabetes, or a 10-year risk score of > or =5%. In the primary prevention subgroup of the 45-64-year-olds, recommended antihypertensive and/or LLD use would be higher in men only, 42% compared with 12% on current medication. Among the 65-79-year-olds, >90% would be eligible for antihypertensives and/or LLDs in both sexes when compared with current treatment rates of <30%. In total, 40% of all participants aged 45-79 would be candidates for primary prevention, compared with 15% on current medication. CONCLUSION: The implementation of the European guidelines could imply a doubling of the numbers of Norwegian adults on cardiovascular medication for primary prevention. Contributors to the increase would be more frequent drug use in men and elderly people, particularly for LLD use.
Authors: H S Haugnes; N Aass; S D Fosså; O Dahl; O Klepp; E A Wist; T Wilsgaard; R M Bremnes Journal: J Cancer Surviv Date: 2008-05-29 Impact factor: 4.442
Authors: Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad Journal: Int J Behav Med Date: 2012-12
Authors: Halfdan Petursson; Johann A Sigurdsson; Calle Bengtsson; Tom I L Nilsen; Linn Getz Journal: J Eval Clin Pract Date: 2011-09-25 Impact factor: 2.431
Authors: David Faeh; Julia Braun; Kaspar Rufibach; Milo A Puhan; Pedro Marques-Vidal; Matthias Bopp Journal: PLoS One Date: 2013-02-14 Impact factor: 3.240
Authors: Theodora Zachariadou; Henri E J H Stoffers; Costas A Christophi; Anastasios Philalithis; Christos Lionis Journal: BMC Health Serv Res Date: 2008-07-16 Impact factor: 2.655